Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IMNM - Immunome Inc


IEX Last Trade
15.19
-0.050   -0.329%

Share volume: 446,163
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$15.24
-0.05
-0.33%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-1.75%
1 Month
-1.75%
3 Months
3.20%
6 Months
-37.94%
1 Year
142.11%
2 Year
166.78%
Key data
Stock price
$15.19
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$6.13 - $30.96
52 WEEK CHANGE
$1.32
MARKET CAP 
911.625 M
YIELD 
N/A
SHARES OUTSTANDING 
60.054 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.34
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$415,369
AVERAGE 30 VOLUME 
$516,148
Company detail
CEO:
Region: US
Website: immunomeinc.com
Employees: 49
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. this proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. we then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.

Recent news